Tezepelumab: A New Treatment for Severe Asthma

Image credit: tezspirehcp.com

What is Tezepelumab used for?

Tezepelumab is indicated for the add-on maintenance treatment of people aged twelve years and older with severe asthma. Two main studies including over 1,500 adults and adolescents with inadequately controlled asthma showed that tezepelumab was effective in reducing the number of severe asthma flare‑ups.

What is Tezepelumab (tezspire®)?

For full details see funding body website. Tezepelumab (Tezspire®) as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment (August 2023)

Is Tezepelumab a monoclonal antibody?

Tezepelumab is a human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. 15 In the phase 2b PATHWAY trial, the annualized rate of asthma exacerbations was up to 71% lower with tezepelumab than with placebo among patients with severe, uncontrolled asthma.

Can Tezepelumab be used for severe asthma?

The clinical experts noted that tezepelumab has the potential to be used for various severe asthma subtypes. They noted that if tezepelumab was approved, people would have another treatment option if their asthma does not respond to current standard care.

What Is Tezepelumab

1. https://bnf.nice.org.uk/drugs/tezepelumab/
2. https://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-is-the-first-biologic-to-consistently-and-significantly-reduce-exacerbations-in-broad-population-of-severe-asthma-patients.html
3. https://en.wikipedia.org/wiki/Tezepelumab
4. https://www.tezspire.com/
5. https://www.nejm.org/doi/full/10.1056/NEJMoa2034975
6. https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire
7. https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00492-1/fulltext
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122263/

Tezepelumab Information

1. https://www.nice.org.uk/guidance/gid-ta10796/documents/129